Berkshire James G. sold (to issuer) $710K of IQV

Berkshire James G. (See Remarks) sold (to issuer) 2,713 shares of IQVIA HOLDINGS INC. (IQV) at $261.54 ($0.71M total) on 2026-09-02.

Original reporting
SEC EDGAR · Berkshire James G.
Published Sep 4, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 10:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IQV
Bearish
medium confidence
Mentioned
$IQV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVBearishLow
01

Why it matters

The disclosed sale provides fresh data for investors assessing insider sentiment and may influence short‑term trading decisions.

02

Market read

New insider sale information for IQVIA, useful for short‑term traders and sentiment analysis.

03

What to watch

Potential tax planning or diversification motives for the insider; not necessarily a bearish signal.

Relevance 5/10Novelty 7/10Timing: filing date 2026-09-04 (after market close)

Background

Form 4 filings disclose insider transactions; they are primary sources for new corporate insider activity.

Company-level read

Ticker impact

$IQVBearishMedium confidence
Context

Officer James G. Berkshire sold 2,713 shares of IQVIA for $709,558 on 2026-09-02, filing a Form 4 on 2026-09-04.

Expected impact

Possible modest dip of 1-2% in the next trading session.

Evidence & confidence

The sale size ($710K) is material for an insider but not large enough to drive a major move; market may react cautiously.

Market effects

Minimal impact on the healthcare data services sector; insider activity is isolated.

U.S. equity markets only; no broader regional effect.

Limited to investors tracking IQVIA.

Counterpoint

The sale could be a routine liquidity event unrelated to company outlook; price may remain stable.

Key entities

  • IQVIA Holdings Inc.

    U.S.-listed provider of health information technologies (ticker IQV).

  • James G. Berkshire

    Company officer who reported the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IQVHighAI 8/10

5 revealing analyst questions from IQVIA’s Q3 earnings call

IQVIA reported Q3 revenue of $4.43 billion, beating estimates by 1.5%, with adjusted EPS of $3.34, a 2% beat. The company raised full-year revenue guidance to $17.43 billion. Analysts discussed AI-driven workflows, margin improvements, and clinical bookings during the earnings call. CEO Ari Bousbib highlighted proprietary data and life sciences expertise as key differentiators.

$IQVMedAI 8/10

IQVIA Holdings Inc (IQV) (Q3 2026) Earnings Call Highlights: Record Bookings, Raised

IQVIA Holdings Inc. reported Q3 2026 earnings with record bookings and raised guidance. Revenue was $4.428B, up 8% YoY, and adjusted EBITDA rose 8.7%. Challenges include FX headwinds and R&D backlog adjustments. Management highlighted AI adoption and strong biotech demand. Full-year 2026 guidance was increased, with revenue expected between $17.35B-$17.5B. No 2027 guidance was provided.

$IQVHighAI 8/10

What IQVIA (IQV) Said on Its Q3 Earnings Call

IQVIA reported Q3 revenue growth of 6.9% to $1.79B, with organic growth at 4%. AI adoption contributed to commercial and clinical momentum, with 415 AI agents deployed. The company raised its 2026 outlook, expecting revenue of $17.35B-$17.50B and adjusted EPS of $12.90-$13.00. Cash flow from operations was $825M, with free cash flow at $667M.

$IQVHighAI 9/10

IQVIA (IQV) Q3 2026 Earnings Call Transcript

IQVIA reported Q3 2026 revenue of $4.43B, up 8%, with organic growth at 6%. Adjusted EBITDA grew 8.7% to $1.03B, and adjusted EPS rose 11.3% to $3.34. R&D solutions revenue increased 8.7%, and commercial solutions revenue grew 6.9%. The company raised full-year revenue guidance to $17.35B-$17.5B. AI deployments and emerging biopharma funding growth were highlighted.